News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Galderma Pharma S.A. and NovaBay Pharmaceuticals, Inc. Enroll First Patients in Phase 2b Clinical Study of NVC-422 for Impetigo


9/24/2012 9:48:53 AM

LAUSANNE, Switzerland and EMERYVILLE, Calif., Sept. 24, 2012 (GLOBE NEWSWIRE) -- Galderma S.A., a global leading pharmaceutical company exclusively focused on dermatology and NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a biotech company developing novel anti-infective products for the treatment and prevention of topical infections, including those caused by antibiotic-resistant bacterial strains, today announced that the first patients have been enrolled in the Companies' Phase 2b clinical study of a proprietary topical formulation of NVC-422 (CD07223) for the treatment of impetigo. The study is expected to enroll over 300 patients at 24 clinical sites in four countries worldwide and aims to confirm efficacy and evaluate 2 different dosage regimens.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES